Literature DB >> 26593299

Liver Transplantation for Cholestatic Liver Diseases in Adults.

Vandana Khungar1, David Seth Goldberg2.   

Abstract

Liver transplantation (LT) is an established lifesaving therapy for patients with cholestatic liver diseases, including primary cholestatic diseases, namely primary sclerosing cholangitis and primary biliary cirrhosis, as well as secondary forms of cholestatic liver disease, including those with cholestatic complications of LT needing a retransplant. Patients with cholestatic liver diseases can be transplanted for complications of end-stage liver disease or for disease-specific symptoms before the onset of end-stage liver disease. These patients should be regularly assessed. Patient survival after LT for cholestatic liver diseases is generally better than for other indications.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cholestatic liver disease; Living donor transplantation; MELD exceptions; Waitlist mortality

Mesh:

Year:  2015        PMID: 26593299      PMCID: PMC4660247          DOI: 10.1016/j.cld.2015.08.011

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  49 in total

1.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

2.  Model for end-stage liver disease-based organ allocation: managing the exceptions to the rules.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-14       Impact factor: 11.382

Review 3.  Liver transplantation for perihilar cholangiocarcinoma.

Authors:  Gregory J Gores; Sarwa Darwish Murad; Julie K Heimbach; Charles B Rosen
Journal:  Dig Dis       Date:  2013-06-17       Impact factor: 2.404

4.  Use of model for end-stage liver disease exceptions for donation after cardiac death graft recipients relisted for liver transplantation.

Authors:  Richard C Maduka; Peter L Abt; David S Goldberg
Journal:  Liver Transpl       Date:  2015-04       Impact factor: 5.799

5.  Regional variability in symptom-based MELD exceptions: a response to organ shortage?

Authors:  C K Argo; G J Stukenborg; T M Schmitt; S C Kumer; C L Berg; P G Northup
Journal:  Am J Transplant       Date:  2011-11       Impact factor: 8.086

6.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

7.  Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.

Authors:  Phunchai Charatcharoenwitthaya; Sylvania Pimentel; Jayant A Talwalkar; Felicity T Enders; Keith D Lindor; Ruud A F Krom; Russell H Wiesner
Journal:  Liver Transpl       Date:  2007-09       Impact factor: 5.799

8.  Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.

Authors:  Kristin Kaasen Jørgensen; Lina Lindström; Milada Cvancarova; Tom H Karlsen; Maria Castedal; Styrbjörn Friman; Erik Schrumpf; Aksel Foss; Helena Isoniemi; Arno Nordin; Kathrine Holte; Allan Rasmussen; Annika Bergquist; Morten H Vatn; Kirsten Muri Boberg
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-16       Impact factor: 11.382

9.  Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.

Authors:  Roman Zenouzi; Tobias J Weismüller; Peter Hübener; Kornelius Schulze; Michael Bubenheim; Nadine Pannicke; Christina Weiler-Normann; Henrike Lenzen; Michael P Manns; Ansgar W Lohse; Christoph Schramm
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-12       Impact factor: 11.382

10.  Spectrum of cancer risk among US solid organ transplant recipients.

Authors:  Eric A Engels; Ruth M Pfeiffer; Joseph F Fraumeni; Bertram L Kasiske; Ajay K Israni; Jon J Snyder; Robert A Wolfe; Nathan P Goodrich; A Rana Bayakly; Christina A Clarke; Glenn Copeland; Jack L Finch; Mary Lou Fleissner; Marc T Goodman; Amy Kahn; Lori Koch; Charles F Lynch; Margaret M Madeleine; Karen Pawlish; Chandrika Rao; Melanie A Williams; David Castenson; Michael Curry; Ruth Parsons; Gregory Fant; Monica Lin
Journal:  JAMA       Date:  2011-11-02       Impact factor: 157.335

View more
  8 in total

1.  Liver Transplant in Patients With Primary Sclerosing Cholangitis.

Authors:  David S Goldberg
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

2.  Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients.

Authors:  Mehmet Sayiner; Maria Stepanova; Leyla De Avila; Pegah Golabi; Andrei Racila; Zobair M Younossi
Journal:  Dig Dis Sci       Date:  2019-08-27       Impact factor: 3.199

3.  Rates of decompensation, hepatocellular carcinoma and mortality in AMA-negative primary biliary cholangitis cirrhosis.

Authors:  Binu V John; Bassam Dahman; Yangyang Deng; Nidah S Khakoo; Tamar H Taddei; David E Kaplan; Cynthia Levy
Journal:  Liver Int       Date:  2021-10-12       Impact factor: 5.828

Review 4.  Secondary Sclerosing Cholangitis in Critically Ill Patients: An Underdiagnosed Entity.

Authors:  Pedro Martins; Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2019-07-30

5.  Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.

Authors:  Binu V John; Nidah S Khakoo; Kaley B Schwartz; Gabriella Aitchenson; Cynthia Levy; Bassam Dahman; Yangyang Deng; David S Goldberg; Paul Martin; David E Kaplan; Tamar H Taddei
Journal:  Am J Gastroenterol       Date:  2021-09-01       Impact factor: 12.045

6.  Liver Transplantation for Recurrent Cholangitis From Von Meyenburg Complexes.

Authors:  Nikhil Panda; Diane Brackett; Corey Eymard; Tatsuo Kawai; James Markmann; Camille N Kotton; Karin Andersson; Heidi Yeh
Journal:  Transplant Direct       Date:  2019-02-11

7.  Mortality on the UNOS Waitlist for Patients with Autoimmune Liver Disease.

Authors:  Jaspreet S Suri; Christopher J Danford; Vilas Patwardhan; Alan Bonder
Journal:  J Clin Med       Date:  2020-01-23       Impact factor: 4.241

Review 8.  Review: Pathogenesis of cholestatic liver diseases.

Authors:  Raquel T Yokoda; Eduardo A Rodriguez
Journal:  World J Hepatol       Date:  2020-08-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.